`Filed: May 12, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`RANBAXY INC.
`
`Petitioner,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC. and JAZZ
`PHARMACEUTICALS IRELAND LTD.
`
`Patent Owner
`
`________________
`
`Case IPR2016-00738
`Patent 9,050,302
`________________
`
`JOINT MOTION TO TERMINATE UNDER 35 U.S.C. § 317(a)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Joint Motion to Terminate
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00738
` Patent 9,050,302
`
`As authorized in the Patent Trial and Appeal Board’s (the “Board”) May 11,
`
`2016 e-mail (Ex. 2001), and pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. §§ 42.72
`
`and 42.74, Patent Owner and Petitioner jointly and respectfully request that the
`
`inter partes review (“IPR”) of U.S. Patent No. 9,050,302 (the “’302 patent”) be
`
`terminated.
`
`1.
`
`Brief Explanation As To Why Termination Is Appropriate
`
`Petitioner filed its petition for IPR on March 10, 2016. (Paper 1.) On March
`
`18, 2016, the Board accorded the petition a filing date, and gave Patent Owner
`
`until June 18, 2016 to file a Preliminary Response. (Paper 4.) The parties
`
`subsequently settled their dispute and executed a confidential settlement agreement
`
`to terminate this proceeding and the parties’ related district court litigation: Jazz
`
`Pharmaceuticals, Inc. et al. v. Amneal Pharmaceuticals, LLC. et al., 13-391-ES-
`
`JAD (D.N.J.). A Stipulation and Order of Dismissal agreed to by the parties in the
`
`related district court litigation is being filed concurrently in the district court.
`
`
`
`Pursuant to 37 C.F.R. § 42.74(b), the parties’ confidential settlement
`
`agreement is in writing, and a true and correct copy is being filed concurrently
`
`
`
`
`2
`
`
`
`IPR2016-00738
`
`Joint Motion to Terminate
` Patent 9,050,302
`
`
`
`
`
`
`
`
`
`
`herewith as Exhibit 2002.1 The parties are also filing concurrently herewith a joint
`
`request to treat the confidential settlement agreement as business confidential
`
`information and keep it separate from the files of the IPR and the involved patent
`
`under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).
`
`Termination of this proceeding is proper under 35 U.S.C. § 317(a) because
`
`the Board has not yet decided whether to institute an inter partes review and has
`
`not yet decided the merits of this proceeding. Further, no other Petitioners remain
`
`in this proceeding, and the parties are unaware of any other matter before the
`
`USPTO that would be affected by the outcome of this proceeding. The related
`
`litigations also involve several patents other than the patent at issue in this IPR.
`
`Accordingly, the parties respectfully request that the Board terminate the inter
`
`partes review of U.S. Patent No. 9,050,302.
`
`2.
`
`Related Litigations Involving The Patent At Issue
`
`The related litigations involving the patent at issue in this proceeding, as
`
`well as the defendants in each case, are set forth below.
`
`
`
`
`
`
`1 The settlement agreement is being filed electronically via the Patent Review
`
`Processing System with access to the “Parties and Board Only.”
`
`
`
`
`3
`
`
`
`Joint Motion to Terminate
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00738
` Patent 9,050,302
`
`Case
`
`Defendants
`
`Jazz Pharmaceuticals, Inc. et al.
`v. Roxane Laboratories, Inc., 15-
`1360-ES-JAD (D.N.J.)
`
`
`
`Jazz Pharmaceuticals, Inc. et al.
`v. Amneal Pharmaceuticals,
`LLC. et al., 13-391-ES-JAD
`(D.N.J.)
`
`Roxane Laboratories, Inc.
`
`Amneal Pharmaceuticals, LLC
`
`Watson Laboratories, Inc.
`
`Lupin Ltd., Lupin Pharmaceuticals Inc., and
`Lupin Inc.
`
`Jazz Pharmaceuticals, Inc. et al.
`v. Par Pharmaceutical, Inc., 15-
`7580-ES-JAD (D.N.J.)
`
`Par Pharmaceutical, Inc.
`
`
`
`3.
`
`Related Proceedings Currently Before The Office
`
`There are no related proceedings currently before the Office involving the
`
`patent at issue.
`
`4.
`
`Current Status Of The Related Litigations
`
`
`
`The litigations against all other defendants remain pending. Each litigation
`
`involves multiple patents and no trial date has been set in any proceeding.
`
`For the foregoing reasons, the parties jointly and respectfully request
`
`termination of the present proceeding.
`
`4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00738
` Patent 9,050,302
`
`
`
`
`
`/S/ Joseph M. Reisman
`
`
`
`
`
`
`
`Joseph M. Reisman (Reg. No. 43,878)
`Carol Pitzel Cruz (Reg. No. 61,224)
`Kerry S. Taylor (Reg. No. 43,974)
`KNOBBE, MARTENS, OLSON & BEAR,
`LLP
`2040 Main Street, 14th Floor
`Irvine, CA 92614
`General Tel: (949) 760-0404
`Fax: (949) 760-9502
`
`Attorneys for Petitioner
`
`Joint Motion to Terminate
`
`
`
`
`
`
`Date: May 12, 2016
`
`Respectfully submitted,
`
`
`
`/S/ F. Dominic Cerrito
`
`
`
`
`
`
`
`
`
`
`
`
`F. Dominic Cerrito (Reg. No. 38,100)
`Eric C. Stops (Reg. No. 51,163)
`Evangeline Shih (Reg. No. 50,170)
`Frank C. Calvosa (Reg. No. 69,064)
`QUINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`General Tel: (212) 849-7000
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`ericstops@quinnmemanuel.com
`evangelineshih@quinnemanuel.com
`frankcalvosa@quinnemanuel.com
`
`Michael Tuscan (Reg. No. 40,210)
`Thomas Blinka (Reg. No. 44,541)
`COOLEY LLP
`1299 Pennsylvania Avenue, NW
`Suite 700
`Washington, DC 20004
`Tel: (202) 842-7800
`Fax: (202) 842-7899
`mtuscan@cooley.com
`tblinka@cooley.com
`
`Attorneys for Jazz Pharmaceuticals
`Ireland Ltd. and Jazz Pharmaceuticals,
`Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`5